Company Management to Present at the Sidoti Emerging Growth Institutional
Investor Forum
PROVO, Utah, April 5 /PRNewswire-FirstCall/ -- Nu Skin Enterprises, Inc.
(NYSE: NUS) today announced that it expects to post record first-quarter
revenue of approximately $288 million, which would be a 9 percent increase
over prior-year results and ahead of previously issued guidance.
"We will generate revenue growth in each of our key markets around the
world during the first quarter and are particularly encouraged by the growth
we are generating in Japan," stated Truman Hunt, president and chief executive
officer. "We anticipate first quarter local currency revenue in Japan to be
up approximately 1 percent year-over-year. The introduction of the Pharmanex
BioPhotonic Scanner in November has enabled us to stem a revenue decline and
generate growth one quarter earlier than expected. In the United States, we
expect to post revenue growth of approximately 14 percent, excluding the
impact of sales to foreign distributors at our international distributor
convention in the first quarter of 2004. Continued growth in the U.S. can be
attributed to the Scanner, along with the recent introduction of compelling
new products. In China, we are encouraged by the successful launch of three
Pharmanex products during the quarter, helping China to achieve approximately
15 percent revenue improvement over the prior year, which is in line with our
expectations.
"Given our strong revenue performance, we anticipate first quarter
earnings per share to be at the top-end or slightly ahead of previous
guidance," concluded Hunt.
The company will release final first quarter financial results in more
detail, along with updated revenue and earnings guidance, on Wednesday,
April 27, 2005 at 11:00 a.m. (EDT).
Additionally, the company will be presenting a business overview to the
investment community at the Sidoti Emerging Growth Institutional Investor
Forum to be held in New York City on Wednesday, April 6, 2005 at 3:15 p.m.
(EDT). The event will not be webcast.
The Company
Nu Skin Enterprises, Inc. is a global direct selling company operating in
40 international markets throughout Asia, the Americas and Europe. The
company markets premium quality personal care products under the Nu Skin(R)
brand, science-based nutritional supplements under the Pharmanex(R) brand, and
technology products and services under the Big Planet(R) brand. Nu Skin,
Pharmanex and Big Planet are registered trademarks of the company and its
affiliates.
Nu Skin Enterprises is traded on the New York Stock Exchange under the
symbol "NUS." Nu Skin Enterprises' press releases are available online at
http://www.nuskinenterprises.com.
Please note: This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934 that
represent the company's current expectations and beliefs, including, among
other things: (i) our anticipated financial results for the first quarter; and
(ii) our beliefs regarding the impact of certain strategic initiatives. The
forward-looking statements and related assumptions involve risks and
uncertainties that could cause actual results and outcomes to differ
materially from any forward-looking statements or views expressed herein.
These risks and uncertainties include, but are not limited to: (a) the
projected financial results are based on preliminary numbers and still need to
be finalized and reviewed by our registered public accounting firm, which
could result in unexpected changes from anticipated results; (b) continued
regulatory scrutiny in China which has from time to time in the past, and
could in the future, negatively impact the company's business, including the
interruption of sales activities in stores and the imposition of fines; (c)
any inability of the company to effectively manage rapid growth in China,
including training and management of a large employed sales force, and
regulatory risks associated with any failure of such sales force to comply
with applicable company policies and government regulations; (d) risks that
the Chinese government fails to adopt or further delays favorable direct
selling regulations, or adopts regulations that negatively impact the
company's current business model there, or that the company is unable to
obtain a direct selling license under these regulations; (e) any inability to
obtain necessary product registrations for its Pharmanex(R) and personal care
products in a timely manner; (f) regulatory risks associated with the
Pharmanex(R) BioPhotonic Scanner, which could inhibit the company's use of
the Pharmanex(R) BioPhotonic Scanner in a market if it is determined to be a
medical device in any market; (g) risks that could adversely impact the
company's operations or financial results in its markets, including its
largest market, Japan, such as any continuation or increase in the impact of
negative market conditions, material decreases in executive level and active
distributors, adverse changes in exchange rates, or the company's inability to
execute effective initiatives in these markets; (h) any failure of current or
planned initiatives or products, including the introduction of the
Pharmanex(R) BioPhotonic Scanner in Japan, China and other markets, to
generate interest among distributors and customers and generate sponsoring and
selling activities on a sustained basis. The company's financial performance
and the forward-looking statements contained herein are further qualified by a
detailed discussion of associated risks set forth in the documents filed by
the company with the Securities and Exchange Commission, including the
company's Annual Report on Form 10-K filed on March 16, 2005. The
forward-looking statements set forth the company's beliefs as of the date of
this release, and the company assumes no duty to update the forward-looking
statements contained in this release to reflect any change.
|
